高危前列腺癌大分割同步整合推量盆腔淋巴结照射联合雄激素剥夺治疗的前瞻性II期试验
这项前瞻性II期试验纳入41例高危前列腺癌患者,采用图像引导的大分割同步整合推量IMRT,25次分割:前列腺67.5 Gy(2.7 Gy/次)、精囊56.25 Gy(2.25 Gy/次)、盆腔淋巴结链50 Gy(2.0 Gy/次),同期联合雄激素剥夺治疗。结果显示晚期泌尿生殖毒性2级为9.8%,晚期胃肠毒性1级和2级分别为14.6%和2.4%,5年生化无复发生存率为95.1%。
要点
- 高危前列腺癌大分割SIB-IMRT联合盆腔淋巴结照射及ADT,晚期2级泌尿毒性9.8%。
- 晚期胃肠毒性1级14.6%、2级2.4%;糖尿病和直肠最大剂量与晚期直肠毒性相关。
- 5年生化无复发生存率95.1%,提示该方案安全有效,值得III期随机试验验证。
核心结论
- 在高危前列腺癌患者中,采用大分割、盆腔淋巴结照射(含髂总淋巴结)和同期ADT的多模式治疗,毒性结果积极且疗效良好。
- 这些有利结果值得进一步开展III期随机试验,以确认全盆腔放疗联合中度大分割和ADT可安全有效地实施。
研究设计与样本
- 前瞻性II期试验,2009年至2012年纳入41例高危前列腺癌患者。
- 所有患者接受图像引导的同步整合推量IMRT,使用三枚金标进行IGRT。
- 放疗方案为25次分割:前列腺总剂量67.5 Gy(2.7 Gy/次),精囊56.25 Gy(2.25 Gy/次),盆腔淋巴结链50 Gy(2.0 Gy/次),同期联合ADT。
- 评估RTOG晚期胃肠和泌尿生殖毒性及6年生化无复发生存率,并与临床因素和剂量学参数进行统计相关性分析。
主要发现
- 晚期泌尿生殖毒性2级发生率为9.8%。
- 晚期胃肠毒性1级和2级发生率分别为14.6%和2.4%。
- 糖尿病和直肠最大剂量似乎是晚期直肠毒性的统计学相关危险因素。
- 5年生化无复发生存率为95.1%。
临床怎么用
- 对于高危前列腺癌,可考虑采用大分割同步整合推量IMRT联合盆腔淋巴结照射及同期ADT的多模式治疗策略。
- 治疗中需关注糖尿病和直肠最大剂量对晚期直肠毒性的影响。
- 该方案的安全性和有效性仍需III期随机试验进一步确认。
局限性
- 本研究为II期试验,样本量有限(41例),结论需更大规模随机试验验证。
- 原文未报告6年生化无复发生存率的具体数值,仅报告5年BRFS为95.1%。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The approach for treating high-risk prostate cancer still presents different unresolved issues. We report the safety and efficacy of a radiation therapy strategy based on the combination of moderate hypofractioned simultaneous integrated boost (SIB) and Image Guidance. MATERIALS AND METHODS: In this phase II trial of patients with high-risk prostate cancer, Image Guided SIB-IMRT plans (Simultaneous Intensity Modulated - Intensity Modulated Radiotherapy) were delivered between 2009 and 2012. All patients enrolled (41) received in 25 fractions a total dose of 67.5 Gy (2.7 Gy/fraction) to the prostatic volume, 56.25 Gy (2.25 Gy/fraction) to the seminal vescicles, and 50 Gy (2.0 Gy/fraction) to the pelvic lymph nodes (LN) chains with concurrent androgen deprivation therapy (ADT). The image-guided radiotherapy (IGRT) procedure was performed using three gold seeds. RTOG late gastrointestinal and genitourinary toxicities and 6-year biochemical relapse-free survival (BRFS) were assessed in combination of their statistical correlation with clinical factors and dosimetric parameters. RESULTS: Rate of late genitourinary toxicity grade 2 was 9.8%, while rates of late gastrointestinal toxicity were 14.6% and 2.4%, for grade 1 and 2, respectively. Diabetes and maximum doses to rectum appeared to be statistically relevant risk factors for late rectal toxicity. Five-year BRFS was 95.1%. CONCLUSIONS: In our study, we observed positive results in terms of toxicity and good efficacy in a cohort of high-risk prostate cancer patients treated with a multimodality therapy approach comprising hypofractionation, irradiation of pelvic nodes (common iliac nodes included), and concurrent ADT. These favorable results may merit further investigation in a phase III randomized trial to confirm that whole pelvic radiation therapy (WPRT) combined with moderate hypofractionation and ADT could be performed safely and effectively.
引用
- Magli A, Moretti E, Tullio A, et al. Hypofractionated simultaneous integrated boost (IMRT-SIB) with pelvic nodal irradiation and concurrent androgen deprivation therapy for high-risk prostate cancer: results of a prospective phase II trial. Prostate Cancer Prostatic Dis. 2018. PMID: 29520019. doi:10.1038/s41391-018-0034-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。